DMPK Scientist

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life‑threatening diseases through the discovery, development, and commercialization of therapies that degrade disease‑causing proteins. Arvinas uses its proprietary PROTACDiscovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC‑targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease‑causing proteins.

Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-102, targeting LRRK2 for neurodegenerative diseases; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic, colorectal, and non‑small cell lung cancers; ARV-393, targeting BCL6 for relapsed/refractory non‑Hodgkin Lymphoma; ARV-027, targeting the polyglutamine‑expanded androgen receptor, or polyQ‑AR, in skeletal muscle; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+ / HER2- breast cancer.

On August 8th 2025, the U.S. Food and Drug Administration accepted the New Drug Application for vepdegestrant, an investigational, orally bioavailable PROTAC estrogen receptor degrader, for its use as a monotherapy in the treatment of adults with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-), ESR1‑mutated advanced or metastatic breast cancer previously treated with endocrine‑based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out‑licensing and commercialization of vepdegestrant.

In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024.

Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, please visit  and connect on Linked In and X.

We have an exciting opening for an experienced DMPK scientist. The incumbent will contribute as a DMPK scientist on project teams from drug discovery through all stages of drug development, with a scientific background on key aspects of DMPK science, including but not limited to in vitro and in vivo ADME, animal PK, toxicokinetics, drug metabolism, DME‑ and transporter‑based DDI, 14C‑ADME studies, QWBA, human PK prediction.

This position reports to the Head of Nonclinical Sciences and may be based at our headquarter location in New Haven, CT or a remote role based within the U.S.

• Serve as a project DMPK scientist and advise discovery teams on strategies for early ADMET profiling up to the selection of lead candidate into preclinical development.
• Represent DMPK function on company‑wide development teams to support the advancement of preclinical and clinical development assets.
• Contribute to the in vitro DDI and other in vitro/in vivo DMPK assessment for individual preclinical drug candidates and ensure timely availability of key data as part of the IND enabling activities.
• Recommend stage appropriate clinical DDI strategy to the clinical pharmacology function.
• Contribute to outsource of DMPK studies and ensure timely and high quality conduct of in vitro and in vivo ADMET studies. Partner with key CROs to develop and customize ADMET assays to support PROTAC drug discovery and development.
• Contribute to the preparation of DMPK component of regulatory documents such as IND, IB, or other documents.
• Stay up to date with the scientific advance and regulatory landscape for DMPK science in drug discovery and development.

• In-depth knowledge or expertise on one or several aspects of DMPK science in drug discovery and/or development, such as biotransformation, bioanalysis, pharmacokinetics, toxicokinetics, DME‑ and transporter‑based drug‑drug interaction, PBPK or PK/PD modeling, human PK prediction.
• General knowledge of drug discovery and development…